MANNKIND CORP 8-K

What Happened
MannKind Corporation announced on May 29, 2026 (8‑K filed June 2, 2026) that the U.S. Food and Drug Administration approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 years and older with type 1 and type 2 diabetes. The FDA also stated that the supplemental biologics license application (sBLA) for this pediatric indication has fulfilled the last remaining postmarketing requirement set out in the original June 27, 2014 approval letter.

Key Details

• Announcement date: May 29, 2026; Form 8‑K filed June 2, 2026 (Item 8.01, Other Events).
• Approved use: Afrezza for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
• FDA determination: The sBLA fulfilled the final postmarketing requirement from the original June 27, 2014 approval.
• Patient context: The filing notes there are more than 350,000 children and adolescents in the U.S. living with diabetes, most with type 1.

Why It Matters
This FDA approval formally expands Afrezza’s label to include pediatric patients aged 6 and up, increasing the product’s eligible patient population (the filing cites >350,000 U.S. children/adolescents with diabetes). The FDA’s statement that the sBLA fulfilled the final postmarketing requirement removes the last outstanding regulatory condition tied to Afrezza’s original approval. The 8‑K does not provide financial forecasts or expected sales impact; investors should look for subsequent company disclosures about commercialization, uptake, and reimbursement for the pediatric indication.